PMID- 27291567
OWN - NLM
STAT- MEDLINE
DCOM- 20170626
LR  - 20220317
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 76
IP  - 5
DP  - 2016 Sep
TI  - Sflt-1 in heart failure: relation with disease severity and biomarkers.
PG  - 411-6
LID - 10.1080/00365513.2016.1190863 [doi]
AB  - Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of 
      endothelial growth factors, such as placental growth factor (PlGF), which 
      modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients 
      with heart failure (HF) and its relationship to adverse cardiovascular (CV) 
      events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels 
      were also determined in healthy volunteers and patients with type 2 diabetes 
      mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in 
      comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of 
      sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP 
      (rho = 0.37, p < 0.01), soluble ST2 (rho = 0.52, p < 0.01), Galectin-3 (rho = 0.38, 
      p < 0.01), aldosterone (rho = 0.25, p = 0.01) and PTH(1-84) (rho = 0.38, p < 0.01). 
      Furthermore, sFlt-1 levels were associated to long-term CV risk. These results 
      suggest a potential role of sFlt-1 in HF and its potential role as biomarker of 
      CV risk.
FAU - Gruson, Damien
AU  - Gruson D
AD  - a Pole de Recherche en Endocrinologie, Diabete et Nutrition, Institut de 
      Recherche Experimentale et Clinique , Cliniques Universitaires St-Luc and 
      Universite Catholique de Louvain , Brussels , Belgium ;
AD  - b Department of Laboratory Medicine , Cliniques Universitaires St-Luc and 
      Universite Catholique de Louvain , Brussels , Belgium ;
FAU - Hermans, Michel P
AU  - Hermans MP
AD  - a Pole de Recherche en Endocrinologie, Diabete et Nutrition, Institut de 
      Recherche Experimentale et Clinique , Cliniques Universitaires St-Luc and 
      Universite Catholique de Louvain , Brussels , Belgium ;
FAU - Ferracin, Benjamin
AU  - Ferracin B
AD  - a Pole de Recherche en Endocrinologie, Diabete et Nutrition, Institut de 
      Recherche Experimentale et Clinique , Cliniques Universitaires St-Luc and 
      Universite Catholique de Louvain , Brussels , Belgium ;
FAU - Ahn, Sylvie A
AU  - Ahn SA
AD  - c Division of Cardiology , Cliniques Universitaires St-Luc and Pole de Recherche 
      Cardiovasculaire, Institut de Recherche Experimentale et Clinique, Universite 
      Catholique de Louvain , Brussels , Belgium.
FAU - Rousseau, Michel F
AU  - Rousseau MF
AD  - c Division of Cardiology , Cliniques Universitaires St-Luc and Pole de Recherche 
      Cardiovasculaire, Institut de Recherche Experimentale et Clinique, Universite 
      Catholique de Louvain , Brussels , Belgium.
LA  - eng
PT  - Journal Article
DEP - 20160613
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - EC 2.7.10.1 (FLT1 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/*blood
MH  - Diabetes Mellitus, Type 2/metabolism
MH  - Female
MH  - Healthy Volunteers
MH  - *Heart Failure/blood/diagnosis/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Placenta Growth Factor/*blood
MH  - Severity of Illness Index
MH  - Vascular Endothelial Growth Factor Receptor-1/*blood
OTO - NOTNLM
OT  - Aldosterone
OT  - BNP
OT  - Galectin-3
OT  - ST2
OT  - heart failure
OT  - prognosis sFlt-1
EDAT- 2016/06/14 06:00
MHDA- 2017/06/27 06:00
CRDT- 2016/06/14 06:00
PHST- 2016/06/14 06:00 [entrez]
PHST- 2016/06/14 06:00 [pubmed]
PHST- 2017/06/27 06:00 [medline]
AID - 10.1080/00365513.2016.1190863 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2016 Sep;76(5):411-6. doi: 
      10.1080/00365513.2016.1190863. Epub 2016 Jun 13.